Pieris Pharmaceuticals Inc.
PIRS
NSC
Sector: Healthcare
Industry: Biotechnology
1.72
USD
-0.10
(-5.49%)
Optionable: Yes Market Cap: 133 M 90-day average vol: 332,581
Previous close: 1.82 Open: 1.78 Bid: 1.77 Ask: 1.77
52 week range
1.54 6.15
Last updated: Friday 5th August 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 5.68 |
Price per Book TTM ($) | 2.47 |
PE Ratio (TTM) | -2.60 |
Book Value per Share ($) | 0.72 |
5 Year PE Range | -18.6 , -3.9 |
Returns
7 Day Return | -4.44% | |
1 Month Return | -13.13% | |
3 Month Return | -26.81% | |
1 Year Return | -52.88% | |
3 Year Return | -65.94% | |
5 Year Return | -67.49% | |
YTD Return | -54.50% |
Risk
Custom Beta One Year | 1.16 |
Custom Beta Three Years | 1.45 |
Beneish M Score | -3.15 |
Altman Z Score | -1.80 |
Financial Health
Technicals
RSI (14 Day) | 38.73 |
14 Day SMA ($) | 1.82 |
14 Day EMA ($) | 1.82 |
Money Flow Index | 76.14 |
Average True Range | 0.10 |
50 Day SMA ($) | 1.83 |
200 Day SMA ($) | 2.94 |
ADX | 45.99 |
MACD | -0.04 |
Growth
Free Cash Flow QoQ Growth | 104.08% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | -46.15% |
Revenue QoQ Growth | 30.14% |
EPS YoY Growth | 0.00% |
Profitability
Chart
News
Pieris Pharmaceuticals (PIRS) Reports Q4 Loss, Tops Revenue Estimates
Yahoo Finance 3/1/2022
Pieris Pharmaceuticals GAAP EPS of -$0.71 beats by $0.17, revenue of $31.41M beats by $5.97M
Seeking Alpha 3/1/2022
Pieris Pharmaceuticals Reports Full-Year 2021 Financial Results and Provides Corporate Update
Yahoo Finance 3/1/2022
Heska (HSKA) Tops Q4 Earnings and Revenue Estimates
Yahoo Finance 2/28/2022
Pieris Pharmaceuticals To Host Full-Year 2021 Investor Call and Provide Corporate Update on March 1, 2022
Yahoo Finance 2/23/2022
Companies Like Pieris Pharmaceuticals (NASDAQ:PIRS) Are In A Position To Invest In Growth
Yahoo Finance 2/4/2022
HTG Appoints Biopharmaceutical Industry Veteran Christopher Kiritsy to its Board of Directors
Yahoo Finance 1/28/2022
3 Biotechs That Will Soar Regardless of COVID-19
Yahoo Finance 1/27/2022
2 Risky Growth Stocks That Could Make You Filthy Rich
Yahoo Finance 1/16/2022
Pieris Is A Biotech To Watch With Extensive Pipeline And Key Partnerships
Seeking Alpha 1/15/2022
Pieris Pharmaceuticals begins dosing in phase 2 gastric cancer study
Seeking Alpha 1/14/2022
Pieris Pharmaceuticals Announces Dosing of First Patient in Phase 2 Gastric Cancer Trial of 4–1BB/HER2 Bispecific Cinrebafusp Alfa
Yahoo Finance 1/14/2022
Pieris: Early Stage Developer Of Novel Asset Class
Seeking Alpha 1/9/2022
Pieris Pharmaceuticals Announces Successful Completion of Safety Milestone and Initiation of Efficacy Portion of Phase 2a Trial of PRS-060/AZD1402
Yahoo Finance 1/3/2022
Do Options Traders Know Something About Pieris Pharmaceuticals (PIRS) Stock We Don't?
Yahoo Finance 12/15/2021
How Many Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Shares Do Institutions Own?
Yahoo Finance 12/6/2021
Pieris Pharmaceuticals To Participate In Upcoming Investor Conferences
Yahoo Finance 11/11/2021
Trend Analysis & Forecast
Read more on this trend analysis & forecast here - uptrenddowntrend.com
Trendlast: -3.342
Financials
PIRS Income Statement
Annual
| Jun-13 | Jun-14 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 5 M | 3 M | 6 M | 25 M | 29 M | 46 M | 29 M | 31 M |
| Cost of sales | 0 | 0 | -366979 | -307906 | -361000 | -369000 | -570000 | -1 M | -2 M | -2 M |
| Gross operating profit | 0 | 0 | 5 M | 3 M | 6 M | 25 M | 29 M | 46 M | 29 M | 31 M |
| Selling Gen & administrative expense | 274 | 15986 | 7 M | 8 M | 9 M | 18 M | 18 M | 18 M | 17 M | 13 M |
| Research & development expense | 0 | 9 M | 6 M | 8 M | 20 M | 22 M | 41 M | 55 M | 47 M | 67 M |
| Operating income | -274 | -15986 | -7 M | -14 M | -23 M | -15 M | -31 M | -27 M | -34 M | -48 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | 0 | 6307 | 3003 | 10905 | 120000 | -2 M | 2 M | -26000 | -4 M | 2 M |
| Pre-tax Income (EBT) | -274 | -15986 | -10 M | -14 M | -23 M | -17 M | -27 M | -25 M | -37 M | -46 M |
| Income taxes | 0 | 0 | -18 | 203866 | 162000 | 1 M | -312000 | 0 | 164000 | 0 |
| Net income from total operations | -274 | -15986 | -10 M | -14 M | -23 M | -18 M | -27 M | -25 M | -37 M | -46 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -274 | -15986 | -10 M | -14 M | -23 M | -18 M | -27 M | -25 M | -37 M | -46 M |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 3 M | N/A | N/A |
| Net income available for common | -274 | -15986 | -10 M | -14 M | -23 M | -18 M | -27 M | -28 M | -37 M | -46 M |
| Depreciation | 0 | 0 | 366979 | 307906 | 361000 | 369000 | 570000 | 1 M | 2 M | 2 M |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -274 | -15986 | -7 M | -13 M | -22 M | -14 M | -30 M | -26 M | -32 M | -46 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | 0 | 0 | -0.71 | -0.41 | -0.55 | -0.4 | -0.5 | -0.56 | -0.68 | -0.71 |
| Diluted EPS total | 0 | 0 | -0.71 | -0.41 | -0.55 | -0.4 | -0.5 | -0.56 | -0.68 | -0.71 |
Top MarketXLS Rank stocks
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started today
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!